ReviewBriefings in bioinformatics2026
A historical journey of metabolite-protein interaction discovery: from data harmonization to AI-driven prediction.
Review in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Metabolites are life-sustaining small molecules produced by living organisms. They interact with proteins involved in metabolism, signalling, and gene regulation, called metabolite-protein interactions (MPIs). This review traces the history of MPI research, from curated resources and early cheminformatics to harmonized identifiers, proteome-scale structural models, and artificial intelligence-driven prediction, while highlighting persistent challenges that continue to limit mechanistic interpretation of metabolomics. Early small-molecule-protein interaction prediction tools (e.g. Molpat and Catalyst) and resources (e.g. ChEMBL and BindingDB) were typically biased towards drug-like molecules. As drug-centred research continued, a revolution in large-scale metabolomics enabled high-throughput profiling of metabolite levels across physiological and disease states. However, these advances also introduced major data integration challenges such as data fragmentation, unresolved metabolite identities, and limited physiological context. Subsequent metabolite-centric resources (e.g. HMDB) and high-throughput screens applied to MPI detection (e.g. thermal proteome profiling) have partially addressed this bias. Proteome-scale structure prediction (e.g. AlphaFold) has further incentivized research into the effects of metabolites on protein structure and function. Nevertheless, the complexity of the biological response also depends on, e.g. exposure, access, and target expression. Looking ahead, MPI research is likely to be shaped by structure-aware deep learning and the integration of MPIs with comprehensive single-cell multi-omics data and host-microbe modelling. These advances may turn metabolomic signals into causal, testable hypotheses, enabling robust systems-level MPI maps for identifying intervention points and designing new treatments. We propose a historically structured roadmap centred on standards-driven data integration and calibrated, structure-aware modelling to support mechanistic, systems-level MPI maps.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.